More Concerns Raised About Possible Risks Of New Heart Failure Drug

More safety concerns are being voiced about Entresto, the new, ballyhooed heart failure drug from Novartis.  Fueling these concerns is a mix of speculation, worry about the FDA’s rapid approval of the drug, and a long-running feud between two leading heart failure researchers. The concerns, raised in a JAMA Viewpoint by heart failure expert, Arthur Feldman, and co-authors Julia Haller and Steven...Click here to continue reading...
Source: CardioBrief - Category: Cardiology Authors: Tags: Heart Failure Policy & Ethics Uncategorized Entresto LCZ macular degeneration neprilysin neurocognitive sacubitril Source Type: blogs